Carolyn Britten, M.D.

Edit your Faculty Profile

A Short Biography:

Dr. Britten’s research focuses on bringing new targeted anti-cancer therapies to the clinic. She is studying signal transduction inhibitors and anti-angiogenesis agents in patients with advanced malignancies and also conducting clinical trials involving hepatocellular cancer and breast cancer.
Work Titles
UCLA Co-Associate Director, JCCC Signal Transduction and Therapeutics Program Area Assistant Professor, Medicine Assistant Professor, Hematology-Oncology
Education:
Degrees:
M.D., University of Toronto Faculty of Medicine, 1992
Fellowship:
1997 - 1999 University of Texas Medical School at San Antonio
1995 - 1997 University of British Colombia (Vancouver)
Internship:
1992 - 1993 University of Western Ontario
Residency:
1993 - 1995 University of Western Ontario
Certifications:
Certifications:
1997 American Board of Internal Medicine
1995 American Board of Internal Medicine

Contact Information:

Work Email Address:

cbritten@mednet.ucla.edu


Website:

Web-Profile

Work Phone Number:

(310) 825-8195

Work Address:

PVUB, Suite 3360
Campus - 707707
CA


Publications:

A selected list of publications:

Britten Carolyn D   PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types Cancer chemotherapy and pharmacology, 2013; 71(6): 1395-409.
Kalous Ondrej, Conklin Dylan, Desai Amrita J, O'Brien Neil A, Ginther Charles, Anderson Lee, Cohen David J, Britten Carolyn D, Taylor Ian, Christensen James G, Slamon Dennis J, Finn Richard S   Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib Molecular cancer therapeutics, 2012; 11(9): 1978-87.
Britten Carolyn D, Gomes Antoinette S, Wainberg Zev A, Elashoff David, Amado Rafael, Xin Yan, Busuttil Ronald W, Slamon Dennis J, Finn Richard S   Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study BMC cancer, 2012; 12(9): 16.
Britten Carolyn D, Finn Richard S, Bosserman Linda D, Wong Steven G, Press Michael F, Malik Mubashira, Lum Bert L, Slamon Dennis J   A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach Clinical breast cancer, 2009; 9(1): 16-22.
Quinn David I, Nemunaitis John, Fuloria Jyotsna, Britten Carolyn D, Gabrail Nashat, Yee Lorrin, Acharya Milin, Chan Kai, Cohen Nadine, Dudov Assen   Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma Clinical pharmacokinetics, 2009; 48(3): 199-209.
Yanagawa Jane, Abtin Fereidoun, Lai Chi K, Yeh Michael, Britten Carolyn D, Martinez Dorothy, Crisera Christopher A, Holmes E Carmack, Lee Jay M   Resection of thyroid cancer metastases to the sternum Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009; 4(8): 1022-5.
Finn Richard S, Bentley Greg, Britten Carolyn D, Amado Rafael, Busuttil Ronald W   Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model Liver international : official journal of the International Association for the Study of the Liver, 2009; 29(2): 284-90.
Britten Carolyn D, Kabbinavar Fairooz, Hecht J Randolph, Bello Carlo L, Li Jim, Baum Charles, Slamon Dennis   A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period Cancer chemotherapy and pharmacology, 2008; 61(3): 515-24.
Camidge D Ross, Gail Eckhardt S, Gore Lia, O'Bryant Cindy L, Leong Stephen, Basche Michelle, Holden Scott N, Musib Luna, Baldwin John, Darstein Christelle, Thornton Donald, Finn Richard S, Britten Carolyn D   A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors Anti-cancer drugs, 2008; 19(1): 77-84.
Lu David S K, Yu Nam C, Raman Steven S, Lassman Charles, Tong Myron J, Britten Carolyn, Durazo Francisco, Saab Sammy, Han Steven, Finn Richard, Hiatt Jonathan R, Busuttil Ronald W   Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation Hepatology (Baltimore, Md.), 2005; 41(5): 1130-7.
Britten CD   Targeting ErbB receptor signaling: a pan-ErbB approach to cancer Molecular cancer therapeutics. , 2004; 3(10): 1335-42.
Britten Carolyn D   Targeting ErbB receptor signaling: a pan-ErbB approach to cancer Molecular cancer therapeutics, 2004; 3(10): 1335-42.
Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA   Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks Invest New Drugs, 2003; 21(1): 85-97.

Does this profile need updating? Contact Us